In an era of cutbacks in basic research by Big Pharma, companies are increasingly relying on academic and nonprofit collaborations for basic science and drug discovery research as output and productivity in the industry are declining.
Meanwhile, for academic researchers, these alliances are becoming just as crucial at a time when funding from the U.S. National Institutes of Health--the world's biggest backer of biomedical research--remains tight. It's a symbiotic relationship that we'll likely continue to see for the foreseeable future as Big Pharma's pipeline dries up and federal R&D spending remains static.
The year isn't over yet, but already some big players have formed some notable unions in 2014.
At the request of Congress, in 2008 NIH began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing. The red and green arrows indicate whether categories had a decrease or bump in funding from the previous year, respectively.
POPULAR COMMENT THREADS
Researchers at the Salk Institute for Biological Studies have uncovered a protein that plays a role in active HIV replication, essentially acting as part of a switch to turn HIV-1, the most common type of HIV, from a dormant state to an active one.
A bacterium found in the gut of an Aedes mosquito may have therapeutic applications for malaria and dengue, two diseases transmitted by these mosquitoes.
Using a new cell programming method, researchers at Washington University in St. Louis have converted human skin cells directly into a type of brain cell that is damaged by Huntington's disease.
Scientists have figured out a way to harness stem cells so that they can be used to produce and emit toxins capable of killing brain tumors.
The White House is temporarily shutting down biomedical research of dangerous pathogens, such as MERS, SARS and pandemic flu strains following several embarrassing safety incidents at government labs.
Investigators have pegged two compounds that appear to reduce inflammation associated with a wide range of diseases such as ulcerative colitis, arthritis and multiple sclerosis.
From Our Sister Sites
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.